Literature DB >> 22156389

Prevalence and mechanism of antimicrobial resistance in Staphylococcus aureus isolates from diseased cattle, swine and chickens in Japan.

Kotaro Baba1, Kanako Ishihara, Manao Ozawa, Masaru Usui, Mototaka Hiki, Yutaka Tamura, Tetsuo Asai.   

Abstract

Antimicrobial administration is essential for the control and treatment of diseases in animals, but the emergence and prevalence of antimicrobial-resistant Staphylococcus aureus is a significant concern during animal production. Here we investigated the antimicrobial susceptibility of S. aureus from diseased food-producing animals and molecularly characterized the methicillin-resistant and fluoroquinolone-resistant isolates. A total of 290 S. aureus isolates obtained from cattle (n=246), swine (n=16), and chickens (n=28) between 2003 and 2009 were examined for antimicrobial susceptibility against 9 antimicrobials using an agar dilution method. Resistance to penicillin (PC) was most frequently found (24.8%), followed by oxytetracycline (OTC, 10.0%), dihydrostreptomycin (4.1%), erythromycin (EM, 3.1%), enrofloxacin (ERFX, 2.1%), and kanamycin (1.7%). The PC resistance rate was significantly higher in swine than in cattle (P<0.01) and chickens (P<0.01). The resistance rates to OTC, EM and ERFX were significantly higher in swine and chickens than in cattle (P<0.05). Methicillin-resistant S. aureus (MRSA) was recovered from milk derived from a cow with mastitis in 2003; sequence type 8, SCCmec type IV and spa type t024. In the six ERFX-resistant strains isolated after 2003, amino acid substitutions in ParC with/without GyrA were detected. As the prevalence of MRSA and FQ-resistant S. aureus in the animals should be noticed, continuous monitoring is necessary to control resistance to clinically important antimicrobials in S. aureus from food-producing animals.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22156389     DOI: 10.1292/jvms.11-0357

Source DB:  PubMed          Journal:  J Vet Med Sci        ISSN: 0916-7250            Impact factor:   1.267


  5 in total

1.  Systemic and mammary gland disposition of enrofloxacin in healthy sheep following intramammary administration.

Authors:  Cristina López; Juan José García; Matilde Sierra; María José Diez; Claudia Pérez; Ana Maria Sahagún; Nélida Fernández
Journal:  BMC Vet Res       Date:  2015-04-09       Impact factor: 2.741

2.  Deoxynybomycins inhibit mutant DNA gyrase and rescue mice infected with fluoroquinolone-resistant bacteria.

Authors:  Elizabeth I Parkinson; Joseph S Bair; Bradley A Nakamura; Hyang Y Lee; Hani I Kuttab; Emma H Southgate; Stéphane Lezmi; Gee W Lau; Paul J Hergenrother
Journal:  Nat Commun       Date:  2015-04-24       Impact factor: 14.919

3.  Assessment of animal diseases caused by bacteria resistant to antimicrobials: Poultry.

Authors:  Søren Saxmose Nielsen; Dominique Joseph Bicout; Paolo Calistri; Elisabetta Canali; Julian Ashley Drewe; Bruno Garin-Bastuji; Jose Luis Gonzales Rojas; Christian Gortazar Schmidt; Mette Herskin; Virginie Michel; Miguel Angel Miranda Chueca; Barbara Padalino; Paolo Pasquali; Helen Clare Roberts; Hans Spoolder; Karl Stahl; Antonio Velarde; Arvo Viltrop; Christoph Winckler; Jeroen Dewulf; Luca Guardabassi; Friederike Hilbert; Rodolphe Mader; Francesca Baldinelli; Julio Alvarez
Journal:  EFSA J       Date:  2021-12-24

4.  First isolation of a methicillin-resistant Staphylococcus aureus from bovine mastitis in Argentina.

Authors:  Mariela E Srednik; Elisa Crespi; María Florencia Testorelli; Tomás Puigdevall; Ana María D Pereyra; María Valeria Rumi; Nicolás Caggiano; Lucía Gulone; Marta Mollerach; Elida R Gentilini
Journal:  Vet Anim Sci       Date:  2018-11-06

Review 5.  Diversity and pathogenesis of Staphylococcus aureus from bovine mastitis: current understanding and future perspectives.

Authors:  Bruno Campos; Amy C Pickering; Lis Souza Rocha; Ananda Pereira Aguilar; Mary Hellen Fabres-Klein; Tiago Antônio de Oliveira Mendes; J Ross Fitzgerald; Andrea de Oliveira Barros Ribon
Journal:  BMC Vet Res       Date:  2022-03-24       Impact factor: 2.741

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.